Effect of Induction Cytarabine Dose Intensity on Long-Term Survival in Acute Myelogenous Leukemia: Results of a Randomized, Controlled Study
- 1 January 1993
- journal article
- clinical trial
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 11 (1-2), 69-77
- https://doi.org/10.3109/10428199309054732
Abstract
The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*/day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71%) and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74%) and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.Keywords
This publication has 13 references indexed in Scilit:
- Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemiaBlood, 1992
- A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.Journal of Clinical Oncology, 1992
- A randomized study of intermediate versus conventional‐dose cytarabine as intensive induction for acute myelogenous leukaemiaBritish Journal of Haematology, 1992
- Therapy of acute myelogenous leukemiaBlood Reviews, 1992
- Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemiaBlood, 1991
- Treatment strategies in acute myeloid leukemia (AML)Blut: Zeitschrift für die Gesamte Blutforschung, 1990
- Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome.Journal of Clinical Oncology, 1989
- Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patientsAmerican Journal Of Medicine, 1988
- Proposals for the Classification of the Acute Leukaemias French‐American‐British (FAB) Co‐operative GroupBritish Journal of Haematology, 1976
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958